Disease overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN)
characterized by stem cell‐derived clonal myeloproliferation that is often but not always …

Myelofibrosis (MF) and polycythemia vera (PV) are BCR-ABL1-negative myeloproliferative
neoplasms associated with somatic hematopoietic stem cell mutations leading to over …

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group
of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia …

Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute
myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of …

Myeloproliferative neoplasms (MPN) in chronic phase that evolve into blast phase (BP) hold
a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape …

Myelofibrosis (MF) is a chronic progressive hematologic malignancy with a median overall
survival (OS) of approximately 6 years. Allogeneic hematopoietic stem cell transplantation …

Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary
hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in …

Primary myelofibrosis, the most aggressive of the classic Philadelphia chromosome‐
negative myeloproliferative neoplasms (MPNs), is a clonal disorder characterized by often …

The article reports a bi-centric experience of six patients who received ruxolitinib in
combination with intensive chemotherapy for myeloproliferative neoplasms in blast-phase …

The discovery of JAK2 V617F a decade ago led to optimism for a rapidly developing
treatment revolution in Ph− myeloproliferative neoplasms. Unlike BCR–ABL, however, JAK2 …